Overcoming current cancer treatment limitations
‘The challenge lies in developing a new generation of tools, capable of simultaneously analysing the vast amount of complex data relating to tumour biology,’ said Filippo de Braud, head of the Department of Oncology and the Medical Oncology Clinic at the National Cancer Institute, Milan. The I3Lung initiative plans to develop a platform for Europe and beyond to capitalize on these new tools for coping with the complexity of available data regarding lung cancer biomarkers.
Retrospective analysis of 2,200 patients treated with first-line immunotherapy between 2012 and 2021 at multiple centres will provide baseline clinical, radiomic, and biological tumour characteristics. ‘In addition, enrolling 200 new patients in a prospective study will generate new multi-omic biological data, including tumour mutational burden, circulating immune biomarkers profiling, digital pathology, gut microbiome, radiomics, and other multi-omics approaches,’ said De Braud. Additionally, a psychological study will be conducted that will incorporate patient experience and preferences to contribute to developing a shared decision support tool. Patients’ tumours will be subjected to state-of-the-art genomic analysis. Six clinical cancer centres based in Italy, Germany, Greece, Spain, Israel, and the United States are involved in these data collection processes.
Source: Healthcare in Europe